$-0.64 EPS Expected for Cidara Therapeutics, Inc. (CDTX) as of May, 9

April 17, 2018 - By Sheila Anderson

Cidara Therapeutics, Inc. (NASDAQ:CDTX) Corporate Logo

Cidara Therapeutics, Inc. (NASDAQ:CDTX)’s earnings report is expected On May, 9., Faxor reports. The earnings per share diference is $0.16 or 20.00 % up from last years number. Previous year: $-0.8; Analysts forcast: $-0.64. Wall Street forecasts -7.25 % EPS growth as of May, 9. On during the last trading session the stock decreased $0.15 or 3.85%, reaching $3.75.Cidara Therapeutics, Inc. has volume of 144,458 shares. Since April 17, 2017 CDTX has declined 44.16% and is downtrending. CDTX underperformed by 55.71% the S&P500.

Cidara Therapeutics, Inc. (NASDAQ:CDTX) Ratings Coverage

Total analysts of 2 have positions in Cidara Therapeutics (NASDAQ:CDTX) as follows: 2 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since November 8, 2017 according to StockzIntelligence Inc Cidara Therapeutics has 3 analyst reports. On Tuesday, February 27 Cantor Fitzgerald maintained the shares of CDTX in report with “Buy” rating. On Thursday, November 9 the stock of Cidara Therapeutics, Inc. (NASDAQ:CDTX) earned “Buy” rating by H.C. Wainwright. On Wednesday, November 8 the rating was maintained by Cantor Fitzgerald with “Buy”.

Cidara Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel anti-infectives for the treatment of various diseases.The firm is valued at $77.89 million. The Company’s lead product candidate is CD101 IV, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of serious, invasive fungal infections.Currently it has negative earnings. The firm also develops CD201, a novel bispecific antimicrobial immunotherapy for the treatment of multidrug-resistant gram-negative bacterial infections, including those caused by pathogens harboring the mcr-1 plasmid.

Cidara Therapeutics, Inc. (NASDAQ:CDTX) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.